Search Results
Your search for ,had matches 18488 pages
Showing 4351 - 4400An AI Model May Predict Elevated Pancreatic Cancer Risk Using Electronic Health Records
An artificial intelligence (AI) model trained using sequential health information derived from electronic health records identified a subset of individuals with a 25-fold risk of developing pancreatic cancer within 3 to 36 months, according to results presented by Placido et al at the American...
Reflections on the Evolution of Clinical Care Since the Passage of the National Cancer Act of 1971
Recently, I had the honor of coauthoring a chapter with Eric P. Winer, MD, President-Elect of ASCO, on the evolution of clinical cancer care since the enactment of the National Care Act of 1971 for the book A New Deal for Cancer: Lessons From a 50-Year War, by Abbe R. Gluck and Charles S. Fuchs,...
Expert Point of View: Mark E. Robson, MD
“OlympiA is clearly a practice-changing trial, and olaparib should be offered to patients meeting the entry criteria for the study,” said Mark E. Robson, MD, Chief of the Breast Medicine Service at Memorial Sloan Kettering Cancer Center, New York. Dr. Robson was invited to discuss the findings of...
OlympiA Trial: Adjuvant Olaparib Significantly Improves Overall Survival in Germline BRCA-Mutated Breast Cancer
The OlympiA trial of adjuvant olaparib in patients with HER2-negative, high-risk early-stage breast cancer and BRCA1 and BRCA2 mutations has now demonstrated a significant overall survival benefit, reducing the risk of death over placebo by 32% and yielding an absolute improvement of 3.8% at 3...
Leader in the Field of Integrative Oncology, Barrie Cassileth, PhD, Dies at 83
In 1999, Memorial Sloan Kettering Cancer Center (MSK) President Paul Marks, MD, recruited Barrie Cassileth, PhD, to establish an Integrative Medicine Service that “provided evidence-based complementary therapies that improve patients’ quality of life by alleviating physical and emotional symptoms...
Childhood Leukemia Pioneer, Donald P. Pinkel, MD, Dies at 95
When St. Jude Children’s Research Hospital was opened in 1962, childhood blood cancer, especially acute lymphoblastic leukemia (ALL), had an exceptionally grim prognosis. However, years of unflagging clinical research led by Donald P. Pinkel, MD, the pediatrician who developed an aggressive...
Having Metastatic Breast Cancer Has Led Me to Focus on What Matters
Nothing can really prepare you for cancer, but it helped that I have dedicated my life in service to others as a minister and advocate for social justice and health equity in breast cancer survivorship. Before my own breast cancer diagnosis in 2016, I had spent years as a volunteer for several...
Use of Traditional Chinese Medicine Herbal Formula Xiao Yao San to Relieve Depression and Anxiety
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Yen Nien (Jason) Hou, PharmD, DiplOM, LAc, and Jyothirmai Gubili, MS, focus on ...
A Lifetime of Pioneering Biologic Research Leads to a New History of Evolution
Although The Social Conquest of Earth was published a decade ago, it is worth revisiting, because, as oncology luminary Harold Varmus, MD, stressed: “It is a tour de force that we ignore at our planet’s peril.” Its author, Edward O. Wilson, PhD, known as “the father of sociobiology,” died at the...
Conundrums of SARS–CoV-2 Infection in Cancer Care
The ASCO Post is pleased to present the Hematology Expert Review, an occasional feature that quizzes readers on issues in hematology. In this installment, Drs. Abutalib, Kröger, and Mikulska focus on the challenges of providing cancer care amid the COVID-19 pandemic. Here they present two...
Ciltacabtagene Autoleucel in Relapsed or Refractory Multiple Myeloma
On February 28, 2022, ciltacabtagene autoleucel was approved for treatment of adults with relapsed or refractory multiple myeloma after at least four lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.1 Ciltacabtagene autoleucel is a...
RELATIVITY-047: Relatlimab Plus Nivolumab Worthy of Further Study in Advanced Melanoma and Beyond
In the recently published results of the RELATIVITY-047 trial,1 summarized in this issue of The ASCO Post, the addition of relatlimab to nivolumab monotherapy was associated with improved progression-free survival compared with nivolumab alone in patients with previously untreated advanced,...
Addition of Anti–LAG-3 Antibody Relatlimab to Nivolumab Improves Progression-Free Survival in Previously Untreated Advanced Melanoma
In a phase II/III trial (RELATIVITY-047) reported in The New England Journal of Medicine, Hussein A. Tawbi, MD, PhD, of The University of Texas MD Anderson Cancer Center, and colleagues found that the addition of relatlimab, a lymphocyte-activation gene 3 (LAG-3)–blocking antibody, to nivolumab...
Expert Point of View: Guru P. Sonpavde, MD
Guru P. Sonpavde, MD, Director of the Bladder Cancer Program at Dana-Farber Cancer Institute, Boston, said the therapeutic landscape of urothelial cancer has been altered by PD-L1 inhibitors and antibody-drug conjugates. “The rationale for Cohort 3 was based on high response rates seen with a...
Second-Line Combination Study in Urothelial Cancer
The combination of the antibody-drug conjugate sacituzumab govitecan-hziy and the immune checkpoint inhibitor pembrolizumab yielded antitumor activity as second-line therapy in patients with platinum-refractory, checkpoint inhibitor–naive, metastatic urothelial cancer, according to the results of...
Research Finds COVID-19 Vaccine Protects Most Patients With Cancer, but Risk Remains Higher for Patients With Blood Cancers
Using the nation’s largest COVID-19 data resource, a research team found that the COVID-19 vaccine offered protection for most patients with cancer. However, patients with certain types of cancer—especially those with hematologic malignancies—had a higher and widely varied risk of breakthrough...
Multilevel Factors Related to Changes in Body Adiposity in Black Survivors of Breast Cancer
In a study reported in the Journal of Clinical Oncology, Qin et al found that gains in body weight and body fat were common in a prospective cohort of Black breast cancer survivors. The researchers also identified factors associated with these changes. As stated by the investigators, “Unfavorable...
Study Identifies Decline in Annual Screening for Breast Cancer Survivors
New research published by Lowry et al in JNCCN—Journal of the National Comprehensive Cancer Network found the rate of mammography participation by breast cancer survivors has been steadily declining since 2009, particularly among younger survivors. The researchers reviewed a nationwide commercial...
Are Disadvantaged Patients Less Likely to Receive Advanced Radiotherapy Techniques for Head and Neck Cancer?
Advanced radiotherapy techniques may reduce the risk of severe and debilitating toxicity associated with radiation, but not all patients have equal access to these modalities, according to data presented at the 2022 Multidisciplinary Head and Neck Cancers Symposium.1 Retrospective analysis of the...
Brazilian Oncologist Antônio Drauzio Varella, MD, Rises From the Streets of São Paulo to International Fame
In this edition of Living a Full Life, Guest Editor Jame Abraham, MD, spoke with Antônio Drauzio Varella, MD, a Brazilian oncologist, educator, scientist, and medical science popularizer in the press and television, as well as a best-selling author. Antônio Drauzio Varella, MD, was born in 1943 in ...
Study Finds Lumpectomy May Be as Effective as Mastectomy for Patients With Nonmetastatic Breast Cancer Younger Than 40
Young women with nonmetastatic breast cancer have similar survival rates whether they are treated with mastectomy or lumpectomy, despite tumors that are typically more aggressive and discovered at a later stage compared to their older counterparts. These findings were from a recent study examining...
Positive Lymph Nodes May Not Be an Indicator for Chemotherapy in Older Patients With Breast Cancer
Positive lymph node status may not be a reliable indicator of the need for adjuvant chemotherapy, and sentinel node biopsy may be unnecessary in older women with certain low-risk cancers, according to a new study presented by Nicholson et al at the American Society of Breast Surgeons 23rd Annual...
Study Finds COVID-19 Restrictions Delayed Breast Cancer Care at a Safety-Net Hospital
The 1-year local COVID-19 restrictions negatively impacted breast cancer stage at presentation, time to treatment, and time to surgery at an urban safety-net hospital, increasing the vulnerability of an already high-risk population. These findings were from a recent study presented by Kapp et al at ...
Prognostic Value of sTILs in Young Women With Node-Negative Triple-Negative Breast Cancer Who Did Not Receive (Neo)Adjuvant Systemic Therapy
In a Dutch retrospective study reported in the Journal of Clinical Oncology, de Jong et al found that higher levels of stromal tumor-infiltrating lymphocytes (sTILs) were associated with “excellent prognosis” in young women with node-negative triple-negative breast cancer who did not receive...
Addition of Carotuximab to Pazopanib in Advanced Angiosarcoma
In the phase III TAPPAS trial reported in JAMA Oncology, Jones et al found that the addition of carotuximab to pazopanib did not improve progression-free survival in patients with advanced angiosarcoma. Carotuximab is an IgG1 antibody that binds endoglin, which is highly expressed on proliferating...
Protecting the Immunocompromised From COVID-19: Practical Information for Physicians
COVID-19 may have caught the world off guard in 2020, but in the 2 years since the pandemic began, several effective monoclonal antibodies and antiviral drugs have emerged to protect the most vulnerable patients. The ASCO Post spoke with Gunjan L. Shah, MD, a hematologic oncologist at Memorial...
FDA Approves Alpelisib for PIK3CA-Related Overgrowth Spectrum
On April 5, the U.S. Food and Drug Administration (FDA) granted accelerated approval to alpelisib (Vijoice) for adult and pediatric patients aged 2 years and older with severe manifestations of PIK3CA-related overgrowth spectrum (PROS) who require systemic therapy. PROS encompasses a group of rare...
Anetumab Ravtansine vs Vinorelbine in Relapsed Mesothelin-Positive Advanced Malignant Pleural Mesothelioma
In the phase II ARCS-M trial reported in The Lancet Oncology, Hedy L. Kindler, MD, FASCO, and colleagues found that the antimesothelin antibody–tubulin inhibitor conjugate anetumab ravtansine did not improve progression-free survival vs vinorelbine as second-line treatment for patients with...
EGFR Inhibition in EGFR-Amplified Advanced Gastroesophageal Cancer
As reported in the Journal of Clinical Oncology by Maron et al, a retrospective study found that use of EGFR inhibitor therapy was associated with benefit in patients with unresectable or metastatic EGFR-amplified gastroesophageal adenocarcinoma. As stated by the investigators, “Subset analyses...
Combined BCMA and CD19 CAR T Cells in Relapsed or Refractory Multiple Myeloma: Long-Term Follow-up
In a long-term follow-up of a Chinese phase II study reported in the Journal of Clinical Oncology, Wang et al found that the combination of anti–B-cell maturation antigen (BCMA) and anti-CD19 chimeric antigen receptor (CAR) T cells produced durable responses and favorable survival outcomes in...
Trials of PARP Inhibitors in Urothelial Cancer: More Questions Than Answers?
Two studies presented at the 2022 ASCO Genitourinary Cancers Symposium explored the role of poly (ADP-ribose) polymerase (PARP) inhibitors in urothelial cancer: ATLANTIS and BAYOU.1,2 Results suggest that PARP inhibitors may be useful in certain genetic subgroups and perhaps in combination with...
Study Explores Racial Disparities Among Patients Undergoing Gastrointestinal Cancer Surgery
Black adult patients are more likely than White patients to receive substandard gastrointestinal cancer surgery, according to a large study led by researchers at Yale Cancer Center published by Bakkila et al in JAMA Network Open. “The COVID-19 pandemic has brought to light previously reported race...
Immune-Related Adverse Events With Immune Checkpoint Inhibitor Treatment for Melanoma in Older White Patients
In a population-based cohort study reported in JAMA Network Open, Schonfeld et al identified the incidence of immune-related adverse events among White patients aged ≥ 65 years with newly diagnosed melanoma treated with immune checkpoint inhibitors. They compared the risk of these adverse events...
Addition of Sorafenib to Standard Chemotherapy in Pediatric Patients With High Allelic Ratio FLT3-ITD–Positive AML
In an analysis from the Children’s Oncology Group protocol AAML1013 reported in the Journal of Clinical Oncology, Pollard et al found that the addition of sorafenib to standard chemotherapy may benefit pediatric patients with high allelic ratio FLT3-ITD–positive acute myeloid leukemia (AML). Study...
Telemedicine vs In-Person Postoperative Follow-up After Inpatient Oncologic Surgery
In a single-institution retrospective study reported in JCO Oncology Practice, Uppal et al found that telemedicine postoperative visits during the COVID-19 pandemic did not result in increased unplanned hospital readmissions vs in-person postoperative visits among patients undergoing elective...
Norman Sharpless, MD, to Step Down as Director of the NCI
Norman E. Sharpless, MD, has announced that he has decided to step down from his position as Director of the National Cancer Institute (NCI), part of the National Institutes of Health, a position he has held since 2017. Dr. Sharpless will continue as NCI Director through April 29, 2022, to allow...
FDA Approves Axicabtagene Ciloleucel for the Second-Line Treatment of Large B-Cell Lymphoma
On April 1, the U.S. Food and Drug Administration (FDA) approved axicabtagene ciloleucel (Yescarta) for adult patients with large B-cell lymphoma (LBCL) who are refractory to first-line chemoimmunotherapy or who experienced relapse within 12 months of first-line chemoimmunotherapy. It is not...
Several Studies Evaluate Agents in the First-Line, Second-Line, and Later Treatment of Advanced Kidney Cancer
The combination of nivolumab plus cabozantinib achieved a continued survival benefit compared with sunitinib in patients with untreated clear cell metastatic or advanced renal cell carcinoma, according to a final overall survival analysis of the phase III CheckMate 9ER trial.1 Additionally,...
DESTINY-Breast03 Trial: T-DXd vs T-DM1 in Previously Treated Patients With Metastatic HER2-Positive Breast Cancer
As reported in The New England Journal of Medicine by Javier Cortés, MD, PhD, and colleagues, the phase III DESTINY-Breast03 trial has shown significantly prolonged progression-free survival with fam-trastuzumab deruxtecan-nxki (T-DXd) vs ado-trastuzumab emtansine (T-DM1) in patients with...
Collaboration Finds International Disparities in Screening, Treatment, and Outcomes for Patients With Lung Cancer
A consensus reached by a lung cancer clinical community within the International Cancer Benchmarking Partnership (ICBP) presented by Lynch et al at the European Lung Cancer Congress (Abstract 196P) has highlighted international disparities in the management and outcomes of patients with lung cancer ...
Association of Serous Tubal Intraepithelial Carcinoma at Risk-Reducing Salpingo-Oophorectomy With Risk of Subsequent Peritoneal Carcinomatosis
Findings from a meta-analysis of individual patient data were reported in the Journal of Clinical Oncology. Steenbeek et al found that among women with BRCA1/2 pathogenic variants who underwent risk-reducing salpingo-oophorectomy for prevention of epithelial ovarian cancer, those with serous tubal...
Study Compares Surveillance Methods and Schedules in Stage I Testicular Seminoma
In the phase III TRISST trial reported in the Journal of Clinical Oncology, Joffe et al found that surveillance with magnetic resonance imaging (MRI) was noninferior to computed tomography (CT) in detecting advanced relapse in patients with stage I testicular seminoma who had undergone orchiectomy...
Registry Study Shows a Real-World Increase in Biomarker Testing Among Patients With Advanced NSCLC
More than half of patients diagnosed with advanced non–small cell lung cancer (NSCLC) undergo biomarker testing, and this figure has increased over the past 5 years, according to real-world data from a Spanish national registry study reported by Calvo de Juan et al at the European Lung Cancer...
ARIEL4 Trial: Rucaparib vs Chemotherapy in Patients With Relapsed Ovarian Cancer and Deleterious BRCA1 or BRCA2 Mutations
As reported in The Lancet Oncology by Rebecca Kristeleit, MD, and colleagues, the phase III ARIEL4 trial has shown a statistically significant improvement in progression-free survival with rucaparib vs chemotherapy in patients with relapsed ovarian cancer and deleterious BRCA1/2 mutations. Study...
Cabozantinib Plus Nivolumab in Advanced Non–Clear Cell Renal Cell Carcinoma
In a single-institution phase II study reported in the Journal of Clinical Oncology, Chung-Han Lee, MD, PhD, and colleagues found that the combination of cabozantinib and nivolumab was active in patients with advanced non–clear cell renal cell carcinoma (RCC) variants, particularly those with...
Study Finds Black Patients With Cancer Diagnosed With COVID-19 Have Worse Outcomes Than White Patients
Black patients with cancer experienced significantly worse outcomes after a COVID-19 diagnosis than non-Hispanic White patients, according to findings published by Fu et al in JAMA Network Open. Investigators from the COVID-19 and Cancer Consortium (CCC19) studied the electronic health records of...
Thickness-Specific Incidence of Cutaneous Melanoma in the United States
In a population-based cohort study reported in JAMA Oncology, Chen et al found that the incidence of overall cutaneous melanoma and thinner tumors was stable in the United States from 2010 to 2018, with an increased incidence of the thickest (T4) melanomas being observed. Lower socioeconomic status ...
Third COVID-19 Vaccine Dose May Improve Immune Response in Patients With Lymphoma
New research has found that the weakened immune systems of patients with lymphoma may improve after they receive a third COVID-19 vaccination. Patients with lymphoma have defects in their immune system that restrict its response to vaccination; despite this, a study published by Lim et al in Nature ...
Risk of Colorectal Cancer May Be Linked to Cumulative Time With Excess Body Weight
In a German study reported in JAMA Oncology, Li et al found that assessment of risk of colorectal cancer based on cumulative lifetime excess weight may be more accurate than risk indicated by single body mass index (BMI) measurements. As stated by the investigators, “Excess weight is associated...
Results From MAPPYACTS Trial Show the Feasibility and Benefit of Molecular Profiling at Cancer Recurrence in Pediatric Patients
Despite advances in treatment for pediatric patients, cancer remains the primary cause of disease-related mortality in children and adolescents. Data from the international clinical trial MAPPYACTS, which aims to define tumor molecular profiles in pediatric patients with recurrent/refractory...
